Literature DB >> 34260381

Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan.

Yohei Kirino1, Kaoru Takase-Minegishi2, Naomi Tsuchida2,3,4, Lisa Hirahara2, Yosuke Kunishita2,5, Ryusuke Yoshimi2, Hideaki Nakajima2.   

Abstract

Entities:  

Keywords:  biological therapy; cytokines; inflammation

Year:  2021        PMID： 34260381     DOI： 10.1136/annrheumdis-2021-220876

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

Review 1.  [VEXAS syndrome].

Authors:  M Zeeck; I Kötter; M Krusche
Journal:  Z Rheumatol       Date:  2022-02-18       Impact factor: 1.372

Review 2.  [Autoinflammation-differences between children and adults].

Authors:  Martin Krusche; Tilmann Kallinich
Journal:  Z Rheumatol       Date:  2021-11-11       Impact factor: 1.372

Review 3.  Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.

Authors:  Carmelo Gurnari; Donal P McLornan
Journal:  Bone Marrow Transplant       Date:  2022-08-08       Impact factor: 5.174

Review 4.  Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.

Authors:  Camila Andrea Guerrero-Bermúdez; Andrés Felipe Cardona-Cardona; Edwin Jesús Ariza-Parra; Juan Ignacio Arostegui; Anna Mensa-Vilaro; Jordi Yague; Gloria Vásquez; Carlos Horacio Muñoz-Vahos
Journal:  Clin Rheumatol       Date:  2022-08-20       Impact factor: 3.650

Review 5.  Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.

Authors:  Keith A Sikora; Kristina V Wells; Ertugrul Cagri Bolek; Adrianna I Jones; Peter C Grayson
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

6.  Adverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS Syndrome.

Authors:  Giulio Ciprian
Journal:  Cureus       Date:  2022-03-24

7.  Thrombosis in VEXAS syndrome.

Authors:  Thet Mon Oo; Jie Tian Jeanette Koay; Siew Fen Lee; Shang Ming Samuel Lee; Xin Rong Lim; Bingwen Eugene Fan
Journal:  J Thromb Thrombolysis       Date:  2021-11-24       Impact factor: 2.300

8.  Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome.

Authors:  Amrita Goyal; Damodaran Narayanan; Waihay Wong; Alvaro C Laga; Nathan T Connell; Susan Y Ritter; Gabriela Cobos
Journal:  JAAD Case Rep       Date:  2022-03-02

9.  Case Report: Tocilizumab Treatment for VEXAS Syndrome With Relapsing Polychondritis: A Single-Center, 1-Year Longitudinal Observational Study In Japan.

Authors:  Yosuke Kunishita; Yohei Kirino; Naomi Tsuchida; Ayaka Maeda; Yuichiro Sato; Kaoru Takase-Minegishi; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

Review 10.  Interleukin-6 inhibition in the treatment of autoinflammatory diseases.

Authors:  Tomohiro Koga; Atsushi Kawakami
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.